Emerging biomarkers for early cancer detection and diagnosis: challenges, innovations, and clinical perspectives.

Journal: European journal of medical research
Published Date:

Abstract

Early detection and accurate cancer diagnosis are crucial for improving patient outcomes and survival rates. This review presents a comprehensive and updated synthesis of emerging biomarkers, essential for providing non-invasive, efficient, and reliable methods to identify cancer in its early stages. An extensive literature review focuses on recent studies and advancements in both traditional and emerging biomarkers, including circulating tumor DNA (ctDNA), exosomes, liquid biopsies, microRNAs (miRNAs), and immunotherapy biomarkers, which show promising potential for early cancer detection. Liquid biopsies, nanobiosensors, artificial intelligence, and next-generation sequencing (NGS) are transforming biomarker discovery and application. Key challenges include low concentration and fragmentation, as well as clearance of ctDNA, the complexity of exosome isolation, inter-patient variability in miRNA expression, and the absence of clinical standardization. We also highlight the translational barriers in low-resource settings and suggest strategies for future implementation. We also underscore the limited diagnostic accessibility in low-resource settings, emphasizing the importance of equity in future applications. Future research should prioritize overcoming current challenges, promoting multidisciplinary collaboration, and creating standardized protocols to enhance the clinical utility of this approach.

Authors

  • Sameen Zafar
    National University of Sciences and Technology, Islamabad, Pakistan.
  • Amna Hafeez
    National University of Sciences and Technology, Islamabad, Pakistan.
  • Hania Shah
    National University of Sciences and Technology, Islamabad, Pakistan.
  • Iqra Mutiullah
    National University of Sciences and Technology, Islamabad, Pakistan.
  • Arslan Ali
    Department of Pathology and Neuropathology, University of Tübingen, Tübingen, Germany.
  • Khushbukhat Khan
    Cancer Clinical Research Unit, Trials360 CRO, Lahore, Pakistan. khan2011@hotmail.com.
  • Gabriela Figueroa-González
    Laboratorio de Farmacogenética, UMIEZ, Facultad de Estudios Superiores Zaragoza, Universidad Nacional Autónoma de Mexico, Ciudad de Mexico, Mexico.
  • Octavio Daniel Reyes-Hernández
    Laboratorio de Farmacogenética, UMIEZ, Facultad de Estudios Superiores Zaragoza, Universidad Nacional Autónoma de Mexico, Ciudad de Mexico, Mexico.
  • Laura Itzel Quintas-Granados
    Colegio de Ciencias y Humanidades, Plantel Cuautepec, Universidad Autónoma de la Ciudad de México, Av. La Corona No. 320, Colonia Loma La Palma, 07160, Ciudad de Mexico, Mexico.
  • Sheila I Peña-Corona
    Departamento de Farmacia, Facultad de Química, Universidad Nacional Autónoma de México, Mexico City, Mexico.
  • Lashyn N Kiyekbayeva
    Department of Pharmaceutical Technology, Kazakhstan Pharmaceutical School, Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan. lashynk@mail.ru.
  • Monica Butnariu
    University of Life Sciences "King Mihai I" From Timisoara, Timisoara, Romania. monicabutnariu@yahoo.com.
  • Cristina-Elena Tota
    University of Life Sciences "King Mihai I" From Timisoara, Timisoara, Romania.
  • Angela Caunii
    "Victor Babes" University of Medicine and Pharmacy Timisoara, 300041, Timisoara, Romania.
  • Dietrich Büsselberg
    Department of Physiology and Biophysics, Weill Cornell Medicine in Qatar, Education City, 24144 Doha, Qatar.
  • Javad Sharifi-Rad
    Universidad Espíritu Santo, Samborondón, 092301, Ecuador. javadsharifirad@uees.edu.ec.
  • Gerardo Leyva-Gómez
    Departamento de Farmacia, Facultad de Química, Universidad Nacional Autónoma de México, Mexico City, Mexico. leyva@quimica.unam.mx.

Keywords

No keywords available for this article.